Kalaris Therapeutics (KLRS) Interest Expenses (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Interest Expenses of $4.6 million for Q1 2026, down 89.63% year-over-year from $44.7 million in Q1 2025, and down 21.16% quarter-over-quarter from $5.9 million in Q3 2025.
Kalaris Therapeutics (KLRS) Interest Expenses (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Interest Expenses history runs 8 years deep, the most recent figure standing at $4.6 million for Q1 2026.
- In Q1 2026, Interest Expenses fell 89.63% year-over-year to $4.6 million; the TTM figure through Mar 2026 stood at $4.6 million (down 89.63% YoY), while the FY2025 annual figure was $9.6 million, down 59.3% from the prior year.
- Interest Expenses for Q1 2026 stood at $4.6 million, down from $5.9 million in the prior quarter.
- The five-year high for Interest Expenses was $44.7 million in Q1 2025, with the low at $100000.0 in Q1 2024.
- The 5-year median for Interest Expenses is $1.5 million (2022), against an average of $4.6 million.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses plunged 95.24% in 2024, then surged 44564.0% in 2025.
- Kalaris Therapeutics' Interest Expenses stood at $1.6 million in 2022, then sank by 43.75% to $900000.0 in 2023, then jumped by 45.44% to $1.3 million in 2024, then surged by 348.74% to $5.9 million in 2025, then slipped by 21.16% to $4.6 million in 2026.
- Business Quant data shows KLRS's Interest Expenses at $4.6 million in Q1 2026, $5.9 million in Q3 2025, and $2.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.67 Mn |
| Jun 30, 2026 | 2.67 Mn |
| Mar 31, 2026 | 4.63 Mn |
| Mar 31, 2026 | 4.63 Mn |
| Sep 30, 2025 | 5.87 Mn |
| Sep 30, 2025 | 5.87 Mn |
| Jun 30, 2025 | 2.13 Mn |
| Jun 30, 2025 | 2.13 Mn |
| Mar 31, 2025 | 44.66 Mn |
| Mar 31, 2025 | 44.66 Mn |
| Dec 31, 2024 | 1.31 Mn |
| Dec 31, 2024 | 1.31 Mn |
| Sep 30, 2024 | 815,000.00 |
| Sep 30, 2024 | 815,000.00 |
| Jun 30, 2024 | 499,000.00 |
| Jun 30, 2024 | 499,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 900,000.00 |
| Dec 31, 2023 | 900,000.00 |